Sartorius reported strong Q1 19 numbers – beating estimates on the top-line as well as the bottom-line. The bioprocess solutions business, up ~21%, was the clear growth driver, more than offsetting the softness in the lab products segment (5.9%). Looking ahead, management reiterated its FY 19 guidance: 7-11% top-line growth and an EBITDA margin of 27%. Factoring in the strong performance, we will be upgrading our estimates marginally. However, our recommendation will remain unchanged.
23 Apr 2019
Off to a good start...
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Off to a good start...
Sartorius AG (0NIQ:LON) | 13,825 0 0.0% | Mkt Cap: 10,352m
- Published:
23 Apr 2019 -
Author:
Virendra Chauhan -
Pages:
3
Sartorius reported strong Q1 19 numbers – beating estimates on the top-line as well as the bottom-line. The bioprocess solutions business, up ~21%, was the clear growth driver, more than offsetting the softness in the lab products segment (5.9%). Looking ahead, management reiterated its FY 19 guidance: 7-11% top-line growth and an EBITDA margin of 27%. Factoring in the strong performance, we will be upgrading our estimates marginally. However, our recommendation will remain unchanged.